OCTADECANOIDS - LINOLEIC ACID METABOLITES

HO-309
(?9-HODE
(?9-Hydroxyoctadeca-10E,12Z-dienoic acid
50 µg/ml ethanol, >99%, MW=296.5, UVmax: 234 nm (23,000), Storage: -20°C.
50 µg
5 x 50 µg
1.0 mg

HO-409
9(S)-HODE
9(S)-Hydroxyoctadeca-10E,12Z-dienoic acid
50 µg/ml ethanol, >99%, MW=296.5, UVmax: 234 nm (23,000) [73543-67-6] Structure - Scheme 8, Storage: -20°C. Biosynthesis by endothelial cells¹, rabbit peritoneal serous membranes², atherosclerotic plaques³ and healthy blood vessels⁴. Biosynthesis via cyclooxygenase⁵ (9-OH stereochemistry was not determined) or lipoxygenase⁶ pathways.
50 µg
5 x 50 µg
1.0 mg

HR-013
(?13-HODE
(?13-Hydroxyoctadeca-9Z,11E-dienoic acid
50 µg/ml ethanol, >99%, MW=296.5, UVmax: 234 nm (23,000) [73804-64-5] Storage: -20°C. Occurence in psoriatic skin⁷.
50 µg
5 x 50 µg
1.0 mg

HO-013
13(S)-HODE
13(S)-Hydroxyoctadeca-9Z,11E-dienoic acid
50 µg/ml ethanol, >99%, MW=296.5, UVmax: 234 nm (23,000) [29623-28-7] Structure - Scheme 8, Storage: -20°C. Biosynthesis in rabbit peritoneal serous membranes², atherosclerotic plaques³, healthy blood vessels⁴, heart mitochondria⁸, psoriatic skin⁹, VX₂ carcinoma cells¹⁰, endothelial cells¹¹, and macrophages¹². Stimulates prostacyclin production by endothelial cells¹³. Inhibits thromboxane production in human platelets¹⁴. Inhibits platelet¹¹ and tumor cell^15,16,17 adhesion to endothelium. Antagonizes 12-HETE induced tumor cell adhesion to endothelium¹⁷. Stimulates DNA synthesis in BALB/c 3T3 fibroblasts¹⁸.
50 µg
5 x 50 µg
1.0 mg

HP-019
9(S)-HPODE
9(S)-Hydroperoxyoctadeca-10E,12Z-dienoic acid
50 µg/ml ethanol, >99%, MW=312.5, UVmax: 234 nm (23,000) [29774-12-7] Structure - Scheme 8, Storage: -20°C.
50 µg
5 x 50 µg

HP-013
13(S)-HPODE
13(S)-Hydroperoxyoctadeca-9Z,11E-dienoic acid
50 µg/ml ethanol, 98%, MW=312.5, UVmax: 234 nm (23,000) [33964-75-9] Structure - Scheme 8, Storage:-80°C. Suppresses activation of platelets¹⁹. Induces endothelial injury²⁰. Constricts isolated coronary arteries²¹. Inhibits prostacyclin synthase²².
50 µg
5 x 50 µg
1.0 mg

KO-013
13-KODE
13-Keto-octadeca-9Z,11E-dienoic acid
50 µg/ml, 98%, MW=294.5, UVmax: 277 nm (22,000)²³, Structure - Scheme 8, Storage: -80°C. Biosynthesis from 13-HODE via dehydrogenases^24,25. Occurs in membranes oxidized by reticulocyte LO²⁶.
50 µg
5 x 50 µg
1.0 mg

LE-009
(?9,10-EODE (9(10)-EpOME, Leukotoxin)
(?9,10-Epoxyoctadec-12Z-enoic acid
50 µg/ml ethanol, 98%, MW=296.5, Structure - Scheme 8, Storage: -20°C. Biosynthesis in leukocytes²⁷, burned skin^28,29 and lung lavages of patients with adult respiratory distress syndrome²⁷. Displays an uncoupling effect on mitochondrial respiration and potent relaxation of rat stomach smooth muscle³⁰. Effects in the cardiovascular system include circulatory collapse³¹, cardiac failure^32,33, vasoconstriction³³ and endothelial cell damage³⁴.
50 µg
5 x 50 µg

LE-012
(?12,13-EODE (12(13)-EpOME)
(?12,13-Epoxyoctadec-9Z-enoic acid
50 µg/ml ethanol, 98%, MW=296.5, Structure - Scheme 8, Storage:-20°C. Biosynthesis in leukocytes^27,30. Cardiovascular effects³³.
50 µg
5 x 50 µg

HO-313
13(S)-HOTE (13(S)-HOTrE)
13(S)-Hydroxyoctadeca-6Z,9Z,11E-trienoic acid
50 µg/ml ethanol, >99%, MW=294.5, UVmax: 236 nm (23,000) [74784-20-6] Storage: -20°C
50 µg
5 x 50 µg
1.0 mg

REFERENCES

1. T.L. Kaduce et al. J. Biol. Chem. 1989 264 6823

2. M. Claeys et al. Biochim. Biophys. Acta 1982 713 160

3. C.J.W. Brooks et al. Atherosclerosis 1971 13 223

4. C.D. Funk et al. J. Biol. Chem. 1985 260 7481

5. F. Engels et al. FEBS Lett. 1986 209 249

6. C.P.A. Van Os et al. Biochim. Biophys. Acta 1979 575 479

7. A.N. Baer et al. J. Lipid Res. 1990 31 125

8. G.A. Blondin Ann. NY Acad. Sci. 1975 264 98

9. R.D.R. Camp et al. Prostaglandins 1983 26 431

10. W.C. Hubbard et al. Prostaglandins 1980 20 431

11. M.R. Buchanan et al. J. Biol. Chem. 1985 260 16056

12. U.F. Schade et al. Biochem. Biophys. Res. Commun. 1987 147 695

13. B.N.Y. Setty et al. Biochem. Biophys. Res. Commun. 1987 146 502

14. 13. B.N.Y. Setty et al. Biochem. Biophys. Res. Commun. 1987 148 528

15. E. Bastida et al. J. Lipid Mediators 1990 2 281

16. T.A. Haas et al. Biochim. Biophys. Acta 1990 1051 174

17. I.M. Grossi et al. Cancer Res. 1989 49 1029

18. W.C. Glasgow and T.E. Eling Mol. Pharmacol. 1990 38 503

19. H. Bult et al. Adv. Prostagland. Thromboxane Leukotriene Res. 1987 17 224

20. M. Mizukami et. al. Arzneim Forsch. 1984 5 569

21. J.Z. Sun et. al. Med. Sci. Res. 1987 15 1449

22. J.A. Salmon et al. Biochim. Biophys. Acta 1978 523 250

23. E. Vioque et al. Arch. Biochem. Biophys. 1962 99 522

24. A.P. Agins et al. Agents Actions 1987 21 397

25. S.M. Earles et al. Biochim. Biophys. Acta 1991 1081 174

26. H. Kuhn et al. Arch. Biochem. Biophys. 1990 279 218

27. M. Hayakawa et al. Biochem. Biophys. Res. Commun. 1986 137 424

28. T. Ozawa et al. Biochem. Biophys. Res. Commun. 1988 152 1310

29. K. Suzuki et al. Burns 1981 8 110

30. T. Ozawa et al. Biochem. Biophys. Res. Commun. 1986 134 1071

31. A. Fukushima et al. Cardiovasc. Res. 1988 22 213

32. S. Sugiyama et al. Life Sciences 1986 40 225

33. M.R. Siegfried et al. Life Sciences 1990 46 427

34. T. Ozawa et al. Am. Rev. Resp. Dis. 1988 137 535